Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
|Articles|May 15, 2020
- Pharmaceutical Technology-05-15-2020
- Volume 2020 eBook
- Issue 2
Best systems and equipment for contamination control
Author(s)Susan Haigney
Pharmaceutical Technology spoke with John Harmer, director, technical sales at Vanrx Pharmasystems about considerations in choosing the best system and equipment for contamination control in pharmaceutical manufacturing.
Advertisement
Pharmaceutical Technology spoke with John Harmer, director, technical sales at Vanrx Pharmasystems about considerations in choosing the best system and equipment for contamination control in pharmaceutical manufacturing.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Page: 41
Articles in this issue
over 6 years ago
On Point: Biologics Drive Growth in Pre-Filled Syringesover 6 years ago
Instrumenting Single-Use Processesover 6 years ago
Considerations in Contamination Controlover 6 years ago
Building Data Quality In Generates Quality Data Outover 6 years ago
Detecting Contamination in Cell Therapiesover 6 years ago
Optimizing Viral Vector Manufacturing for Gene Therapyover 6 years ago
Minimizing Contamination During Biopharma R&Dover 6 years ago
Complications in Process Simulation ExecutionAdvertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement